Key result
Kidney transplantation in candidates with nonmultiple myeloma plasma cell dyscrasias provides good outcomes with low recurrence rates if treated with a complete or good partial response prior.
Why the study?
Advances in treating plasma cell dyscrasias have improved survival and may allow kidney transplantation in previously ineligible candidates, as well as affect recipients who develop these disorders post-transplantation.
Should patients with a history of plasma cell dyscrasias be considered for kidney transplantation?
Should patients with a history of plasma cell dyscrasias be considered for kidney transplantation?
Transplant candidates with a history of plasma cell dyscrasia who are in remission should not be excluded from kidney transplantation.
Answers are grounded in this paper and cite their sources.
Advances in plasma cell dyscrasia therapies may expand kidney transplant eligibility; leaves open optimal post-transplant management strategies.
PURPOSE OF REVIEW: Plasma cell dyscrasias encompass a group of hematological disorders characterized by increased production of immunoglobulins by clonal B cells. Kidney involvement is common. Significant advances in the treatment of plasma cell dyscrasias have resulted in improved survival and may permit kidney transplantation in candidates previously denied transplantation. Treatments may also have effects on kidney transplant recipients who develop plasma cell dyscrasias post transplantation. RECENT FINDING: The available evidence suggests that transplantation of candidates with nonmultiple myeloma plasma cell dyscrasias provides good outcome with low recurrence rates, so long as the disease has been treated with a complete or good partial response prior to transplantation. Candidates with a history untreated MGRS or a history of multiple myeloma have a high rate of recurrence posttransplant. Kidney transplant recipients who develop plasma cell dyscrasias post transplantation have an increased risk of death and thalidomide-based regimens may increase the risk of rejection. SUMMARY: Transplant candidates with a history of plasma cell dyscrasia who are in remission should not be excluded from transplantation. Individuals with multiple myeloma have a high rate of recurrence and myeloma post kidney transplant must be managed carefully.
No takes yet. Share an insight, caveat, or question.
Lum et al. (2019) conducted a review in Plasma cell dyscrasias and kidney transplantation. Kidney transplantation was evaluated. Kidney transplantation in candidates with nonmultiple myeloma plasma cell dyscrasias provides good outcomes with low recurrence rates if treated with a complete or good partial response prior.
Synapse has enriched 10 related papers. Consider them for comparative context: